Novo Nordisk
Novo Nordisk A/S is a Danish global healthcare company and one of the central companies in the modern obesity-treatment industry. Its obesity portfolio connects Wegovy, Saxenda, semaglutide, liraglutide, GLP-1 and amylin-related development programs, manufacturing capacity, regulatory milestones, and treatment-access channels.
The company and pipeline record reviewed here is current to July 23, 2026. Product labels, trial status, regulatory reviews, leadership, commercial channels, and manufacturing arrangements can change; dated primary records should be checked before treating a relationship as current.
Reference record
Section titled “Reference record”| Field | Novo Nordisk record |
|---|---|
| Legal name | Novo Nordisk A/S |
| Headquarters | Bagsværd, Denmark |
| Industry roots | Danish insulin activities beginning in 1923; present company formed through the 1989 merger of Novo and Nordisk |
| President and CEO | Maziar Mike Doustdar |
| Listed securities | B shares on Nasdaq Copenhagen under NOVO-B; American Depositary Receipts on the New York Stock Exchange under NVO |
| Controlling ownership | Novo Holdings A/S, wholly owned by the Novo Nordisk Foundation, holds the majority of votes |
| Core obesity products | Wegovy and Saxenda |
| Principal obesity-market ingredients | Semaglutide and liraglutide |
| Selected late-stage obesity assets | CagriSema, cagrilintide, and zenagamtide |
Novo Nordisk’s 2025 annual report and company overview support the current corporate identity and leadership fields. The annual report describes Maziar Mike Doustdar as president and CEO and reports Lars Rebien Sørensen as chair of the board.
Why Novo Nordisk matters in obesity treatment
Section titled “Why Novo Nordisk matters in obesity treatment”Novo Nordisk links several generations of the prescription obesity market. Saxenda connects the company to the earlier liraglutide era of GLP-1 obesity products. Wegovy connects it to injectable and oral semaglutide, cardiovascular outcomes, MASH, global manufacturing expansion, and a much larger commercial market.
The portfolio also reaches beyond approved GLP-1 products. CagriSema combines semaglutide with the amylin analogue cagrilintide, while zenagamtide combines GLP-1 and amylin receptor activity in a single investigational molecule. These programs show how the company is extending its obesity strategy from single-mechanism GLP-1 products toward combination and multi-receptor approaches.
Approved and adjacent product portfolio
Section titled “Approved and adjacent product portfolio”| Product | Active ingredient | Company and market relationship | Status boundary |
|---|---|---|---|
| Wegovy | Semaglutide | Novo Nordisk’s principal current obesity product, with US injection and tablet records | Indications and populations differ by formulation; current label scope should be checked product by product |
| Saxenda | Liraglutide | Earlier once-daily injectable GLP-1 obesity product | Separate product, label, dose, and regulatory record from Wegovy |
| Ozempic | Semaglutide | Diabetes-market product that shares the semaglutide platform and manufacturing context | Not an obesity product merely because it shares semaglutide with Wegovy |
| Rybelsus | Semaglutide | Oral diabetes-market semaglutide product and an important formulation-development predecessor | Separate from Wegovy tablets and not interchangeable on a milligram-for-milligram basis |
| Victoza | Liraglutide | Diabetes-market product related to the same ingredient platform as Saxenda | Separate product and indication record |
Current US product identity and label scope are supported by the DailyMed Wegovy label and product-specific records linked from the drugs directory.
Obesity and metabolic pipeline
Section titled “Obesity and metabolic pipeline”Pipeline status is dated and should not be interpreted as approval or market availability.
| Asset or program | Mechanism or composition | Status as reviewed | Relationship to the company portfolio |
|---|---|---|---|
| CagriSema | Fixed-dose cagrilintide 2.4 mg and semaglutide 2.4 mg combination | Novo Nordisk submitted an NDA to FDA on December 18, 2025; the company said FDA review was expected in 2026 | Connects the established semaglutide platform to an amylin analogue and the REDEFINE clinical program |
| Cagrilintide | Long-acting amylin analogue | Phase 3 RENEW program reported in the 2025 annual report | Provides both a standalone amylin program and a component of CagriSema |
| Zenagamtide, formerly amycretin | Unimolecular GLP-1 and amylin receptor agonist with subcutaneous and oral programs | Novo Nordisk reported initiation of the obesity-focused AMAZE phase 3 program in the first quarter of 2026 | Extends the portfolio beyond fixed-dose combinations to one molecule engaging both receptor systems |
| UBT251 | Investigational triple agonist | Phase 1b/2a obesity development reported in Novo Nordisk’s first-quarter 2026 materials | Adds a licensed multi-receptor program to the earlier internal incretin and amylin portfolio |
| Efruxifermin | FGF21 analogue | Phase 3 MASH asset added through the acquisition of Akero Therapeutics completed in 2025 | Expands the company into an obesity-related liver-disease market beyond semaglutide |
Novo Nordisk’s 2025 innovation and pipeline review, first-quarter 2026 results, and December 2025 CagriSema filing announcement provide the dated status context. Company-reported trial results and development plans require confirmation from trial registries, peer-reviewed publications, or regulatory records when used for efficacy comparisons.
Clinical-program relationships
Section titled “Clinical-program relationships”| Program | Company relationship | Connected record |
|---|---|---|
| STEP | Novo Nordisk-sponsored semaglutide weight-management development program | Semaglutide, Wegovy, and adult and pediatric obesity studies |
| SELECT | Novo Nordisk-sponsored cardiovascular outcomes program | Wegovy’s US cardiovascular-risk indication in a defined adult population |
| ESSENCE | Novo Nordisk-sponsored MASH program | Wegovy injection’s accelerated-approval MASH indication and ongoing confirmatory evidence |
| OASIS | Oral semaglutide development program | Wegovy tablet development and the broader oral semaglutide platform |
| REDEFINE | CagriSema phase 3 program | Investigational cagrilintide/semaglutide fixed-dose combination |
| RENEW | Cagrilintide phase 3 program | Standalone amylin-analogue development |
| AMAZE | Zenagamtide obesity phase 3 program | Subcutaneous and oral GLP-1/amylin development |
Trial-level claims belong in clinical-program records that preserve trial identifiers, populations, comparators, durations, endpoints, status dates, and sources.
Regulatory relationships
Section titled “Regulatory relationships”Novo Nordisk’s company record connects to product-specific approvals rather than one company-wide regulatory status.
| Date | Event | Company significance |
|---|---|---|
| December 23, 2014 | FDA approved Saxenda for chronic weight management | Established the company’s liraglutide obesity-product record |
| June 4, 2021 | FDA approved Wegovy injection | Established semaglutide as Novo Nordisk’s principal US obesity product |
| December 23, 2022 | FDA expanded Wegovy injection to a defined pediatric obesity population aged 12 years and older | Extended the product’s population scope |
| March 8, 2024 | FDA added Wegovy’s cardiovascular-risk-reduction indication | Connected Novo Nordisk’s obesity portfolio to cardiovascular outcomes and payer-policy discussions |
| August 15, 2025 | FDA granted accelerated approval to Wegovy injection for a defined noncirrhotic MASH population | Added an obesity-related liver-disease indication and confirmatory-evidence obligation |
| December 2025 | FDA approved Wegovy tablets, and Novo Nordisk submitted CagriSema for FDA review | Expanded the commercial semaglutide platform while advancing a separate investigational combination |
| March 19, 2026 | FDA approved the 7.2 mg Wegovy HD injection dose for certain adults | Expanded the Wegovy injection presentation and dose landscape |
These events are linked to primary sources in the Wegovy product record and regulatory milestones. A company relationship does not transfer an approval from one product, formulation, indication, population, or jurisdiction to another.
Manufacturing and supply network
Section titled “Manufacturing and supply network”Novo Nordisk’s obesity position depends on active-ingredient production, formulation, fill-finish, device, packaging, and distribution capacity rather than a single manufacturing site.
The company reported that Wegovy tablets for the US use semaglutide active pharmaceutical ingredient produced at Clayton, North Carolina, with tablets made and packed at Durham, North Carolina. It also completed the acquisition of three former Catalent manufacturing sites in Bloomington, Indiana; Brussels, Belgium; and Anagni, Italy, on December 18, 2024. Novo Nordisk described those sites as additions to its fill-finish capacity and broader supply network.
The 2025 commercial and manufacturing review and Catalent-site completion announcement support these dated company records. They do not establish which facility made a particular dispensed unit, current output at each site, local pharmacy inventory, or uninterrupted availability.
FDA determined on February 21, 2025, that the national shortage of semaglutide injection products, including Wegovy and Ozempic, was resolved. FDA also noted that intermittent localized supply disruptions could still occur. That shortage determination is a dated US supply record, not a universal availability statement.
Ownership and governance
Section titled “Ownership and governance”Novo Nordisk combines public-market listings with foundation control. Novo Holdings A/S, which is wholly owned by the Novo Nordisk Foundation, holds the majority of votes at Novo Nordisk A/S general meetings.
As of December 31, 2025, the company reported that Novo Holdings controlled 77.3% of votes while holding 28.1% of shares. Novo Nordisk’s B shares were listed on Nasdaq Copenhagen, and its American Depositary Receipts were listed on the New York Stock Exchange. These are corporate identity and governance facts, not an investment assessment.
The dated ownership figures and structure are documented in the 2025 annual report’s value-creation record and corporate-governance record.
Selected industry-shaping transactions
Section titled “Selected industry-shaping transactions”| Date | Transaction or relationship | Obesity-industry relevance |
|---|---|---|
| December 18, 2024 | Acquisition of three former Catalent manufacturing sites from Novo Holdings | Expanded fill-finish capacity and supply-chain flexibility for current and future products |
| 2025 | Licensing of UBT251 and an early-stage glucagon program from United Biotechnology | Added externally sourced multi-receptor obesity and diabetes assets |
| 2025 | Acquisition of Akero Therapeutics | Added phase 3 efruxifermin and expanded the company’s MASH portfolio beyond Wegovy |
Transaction records should preserve completion date, acquired or licensed asset, development status, territory, and source. They should not be generalized into current product ownership or commercialization claims without a dated agreement or company filing.
Company-history context
Section titled “Company-history context”Novo Nordisk traces its industry roots to Danish insulin production beginning in 1923. Novo and Nordisk developed as separate companies and competitors before merging in 1989 to form Novo Nordisk A/S. This history matters to obesity-industry research because the company’s later GLP-1 portfolio emerged from a much older diabetes, peptide, device, and manufacturing platform.
The company’s heritage record supports the 1923 roots and 1989 merger. The history should not be read as evidence that every later product, ingredient, mechanism, or business unit existed throughout that period.
Interpretation boundaries
Section titled “Interpretation boundaries”- Novo Nordisk’s connection to a product does not by itself identify the physical manufacturer, packager, distributor, approval holder, or commercial partner in every jurisdiction.
- A pipeline asset is not an approved or commercially available product.
- A submitted regulatory application is not an approval.
- Shared company ownership or active ingredient does not make Wegovy, Ozempic, Rybelsus, Saxenda, or Victoza interchangeable.
- Company-reported trial results should retain study design, population, endpoint, analysis, and source context.
- FDA approval or resolved national shortage status does not establish local launch, inventory, coverage, reimbursement, price, or affordability.
- Corporate and financial records are included for industry identity and relationship mapping, not investment advice.
Related records
Section titled “Related records”- Wegovy for the principal obesity-product record
- Semaglutide for the active-ingredient platform
- Companies for the industry company directory
- Weight loss drug manufacturers and commercial partners for company-role distinctions
- Mechanisms for GLP-1, amylin, and combination-development context
- Clinical programs for STEP, SELECT, ESSENCE, OASIS, REDEFINE, RENEW, and AMAZE relationships
- Regulatory milestones for dated product-level events